Company Profile

Biousian Biosystems Inc (AKA: BBI)
Profile last edited on: 1/22/19      CAGE: 50Z07      UEI:

Business Identifier: Drugs with unique selectivity and potency for GPCR targets: Chronic pain
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

51 Follen Road
Lexington, MA 02421
   (781) 652-0200
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

Previously based in Maine, Biousian Biosystems Inc (BBI) is focused to improving the lives of patients living in chronic pain or struggling conditions which lead to chronic pain. Using its Carbosyn technology platform, BBI builds drugs that have unique selectivity and potency for targets called G-protein coupled receptor or “GPCRs”. The company has specific strengths in related medicinal chemistries and pharmacology. For clinical validation BBI strives to work closely with development partners whose interests and expertise include seeking FDA approval and subsequent product commercializatio

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2012 2 NIH $1,182,513
Project Title: Novel Glycosylated Delta Opioid Receptor Agonists for Chronic Inflammatory Pain

Key People / Management

  Mark Philip -- Non-executive Chairman

  Edward J Bilsky

  Kimberley Sue Gannon

  Christine M Kitsos

  Robert G Urban -- President